A retrospective study of 114 oculoplastic surgery patients found trehalose added to sodium hyaluronate improved tear break-up time, corneal staining, and meibomian gland loss compared with sodium hyaluronate alone, particularly after eyelid reconstruction.
For Jay S. Duker, MD, and Ramiro Ribeiro, MD, PhD, paths that began in clinical and academic medicine became the foundation for a different kind of work—leading drug development from the inside.
A prospective pilot series finds Keraring implantation cuts refractive cylinder by 61% in non-ectatic corneas, opening a new conversation about ICRS indications.
The 2-day program at the Gaylord Opryland Resort will bring together established and emerging eye care leaders for sessions on leadership development, artificial intelligence, inclusion, and career growth.
The CE-marked lens is being placed by selected surgeons across 6 European countries under a company-described early-access program
Douglas D. Koch, MD, and Karolinne Maia Rocha, MD, PhD, discuss the optics behind enhanced monofocal lenses, patient selection, and how to set expectations.
A balanced mix of AI-generated and smartphone-captured images eliminated the domain-specific failures seen with single-source training
The resubmission is considered a Class 1 submission and has a current PDUFA target action date of July 29, 2026.
Belite Bio has completed its rolling NDA submission to the FDA for tinlarebant, a potential first approved treatment for Stargardt disease type 1.
Retina cells that sense light falter in Alzheimer’s, potentially derailing sleep and body clocks—pointing to new diagnostic and treatment angles.
Immediate flushing of the eye can significantly reduce long-term damage after chemical exposure
StemSight secures new patents for scalable induced pluripotent stem cells-derived limbal stem cells, boosting STE-101’s path to off-the-shelf limbal stem cell deficiency therapy and upcoming Series A.
Optical coherence tomography angiography found distinctive microvascular signatures in the retinal layers associated with various stages of decline in cognition.
SOL-1 data show OTX-TKI extends rescue-free control in treatment-naive wet AMD, shaping AI-driven trial design and longer-interval care.
A midyear recap of the cataract-related news Ophthalmology Times has covered in 2026
Learn how FDA’s interchangeable ranibizumab biosimilar may streamline injections, cut costs, and guide safe switching for retina patients.
Host Deborah Ristvedt, DO, welcomes Vance Thompson, MD, to discuss how prioritizing people has shaped the culture and growth of Vance Thompson Vision.
Step-by-step prompting boosts multimodal AI accuracy on bilingual ophthalmology vignettes with images—but weak subspecialty and image-reading skills remain.
A retrospective study identifies thin choroid as the key factor behind ungradable ultrawidefield green-light fundus autofluorescence images in geographic atrophy.
After accounting for key factors like eye length, researchers found no meaningful differences in corneal biomechanics between primary open-angle and primary angle-closure glaucoma.
A case report describes image-guided surgical excision combined with adjunctive cryotherapy and a single anterior chamber methotrexate injection, with no recurrence at 10 months.
In part 2 of a 2-part Q&A, John Berdahl, MD, weighs in on AI-driven IOL power calculation in challenging eyes, best practices for reducing posterior capsule opacification, and how surgical mission work abroad has shaped his approach in the OR.
Alkeus Pharmaceuticals has dosed the first participant in the phase 3 NORTHSTAR trial of oral gildeuretinol for Stargardt disease, a condition with no approved treatments.
Three-year gene therapy data, an FDA reversal in wet AMD, light-powered dry eye treatment, a new macular supplement, and progress in childhood glaucoma—our review breaks down the 5 May 2026 stories that matter.
In the latest episode of The Retina TL;DR with Dr. Weng, host Christina Y. Weng, MD, MBA, FASRS, talks with Dr. Eichenbaum about the cell and gene therapy pipeline ahead, what sustains a career in retina, and why lifting others up is just what you do.
The update introduces a 250 kHz scan speed for OCT Angiography combined with enhanced TruTrack Active Eye Tracking, as well as new multimodal imaging capabilities, including the Green Autofluorescence Module
The FDA approved the TECNIS PureSee IOL (model ZEN00V) on March 12, 2026.
New phase 3 trial tests rhNGF eye drops for persistent corneal epithelial defects, aiming for full healing and a first approved PCED therapy.
Alkeus Pharmaceuticals has dosed the first participant in the phase 3 NORTHSTAR trial of oral gildeuretinol for Stargardt disease, a condition with no approved treatments.
Finding satisfaction in ocular research—considerations about AI and enhanced datasets.
